Neogenomics

Neogenomics FCF CAGR 5Y

The FCF CAGR (5 Year) of Neogenomics (NEO) as of Nov 5, 2026 is -4.65 %.

FCF CAGR 5Y

-4.65 %

Last updated:

FCF CAGR (5 Year) of Neogenomics is 2025 -4.65 % . FCF CAGR (5 Year) of Neogenomics was 2024 - . It decreases by % lower compared to the previous year.

The Neogenomics FCF CAGR 5Y history

The Neogenomics FCF CAGR 5Y history
YEARFCF CAGR 5YYoY
-4.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neogenomics Stock analysis

What does Neogenomics do? Neogenomics Inc. is a leading company in the field of personalized medicine, based in Fort Myers, Florida. It offers integrated diagnostics and pharmaceutical services for oncology and gene therapy, with a focus on providing accurate diagnosis for cancer patients. Neogenomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neogenomics stock

FCF CAGR (5 Year) of Neogenomics is -4.65 % in 2025.

On Eulerpool you can find the complete historical development of FCF CAGR (5 Year) Neogenomics since 2006 – with annual values, charts, and detailed analysis.

The 5-year FCF CAGR shows the compound annual growth rate of free cash flow over five years.

To evaluate FCF CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF CAGR (5 Year).

FCF CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track FCF CAGR (5 Year)'s Neogenomics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Neogenomics

All Key Metrics — Neogenomics